SCHEMBL19837996

SCHEMBL19837996

Cn1ccc2c1c1c(N)ncnc1n2[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADK P55263 6/20 0.69
▸ CDK5 Q00535 2/20 0.58
▸ CDK5R1 Q15078 1/20 0.58
▸ CDK2 P24941 3/20 0.56
▸ CDK1 P06493 2/20 0.56
▸ CCNA2 P20248 2/20 0.56
▸ CCNA1 P78396 2/20 0.56
▸ CCNB1 P14635 1/20 0.56
▸ HSPA8 P11142 4/20 0.56
▸ HSPA5 P11021 2/20 0.54
▸ HIF1A Q16665 1/20 0.54
▸ DOT1L Q8TEK3 1/20 0.53
▸ DCLK1 O15075 1/20 0.53
▸ DAPK3 O43293 1/20 0.53
▸ DYRK3 O43781 1/20 0.53
▸ ROS1 P08922 1/20 0.53
▸ RPS6KB1 P23443 1/20 0.53
▸ FLT3 P36888 1/20 0.53
▸ CSNK1A1 P48729 1/20 0.53
▸ CSNK1D P48730 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19837990 0.88 ADK (0.70) ADKCDK5CDK5R1CDK2CDK1
SCHEMBL19837963 0.88 ADK (0.69) ADKCDK5CDK5R1CDK2CDK1
SCHEMBL19837981 0.86 ADK (0.67) ADKCDK5CDK5R1HSPA8HSPA5
SCHEMBL21351731 0.86 ADK (0.67) ADKCDK5CDK5R1CDK2CDK1
SCHEMBL21351720 0.86 ADK (0.67) ADKCDK5CDK5R1HSPA8HSPA5
SCHEMBL19837987 0.86 ADK (0.67) ADKCDK5CDK5R1CDK2CDK1
SCHEMBL19837970 0.86 ADK (0.67) ADKCDK5CDK5R1CDK2CDK1
SCHEMBL21351704 0.82 ADK (0.72) ADK
SCHEMBL19837994 0.82 ADK (0.72) ADK
SCHEMBL21351701 0.82 ADK (1.00) ADKCDK2CCNA2CCNA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10730905-B2 Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2020-08-04 — — US claimed
EP-3494122-B1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2019-09-18 — — EP claimed
EP-3494122-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) 2019-06-12 — — EP claimed
US-20190144486-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-05-16 — — US claimed
WO-2018024265-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2018-02-08 — — WO claimed
US-10730905-B2 Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2020-08-04 — — US disclosed
US-10730905-B2 Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2020-08-04 — — US disclosed
EP-3494122-B1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2019-09-18 — — EP disclosed
EP-3494122-B1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR V V I (CZ) 2019-09-18 — — EP disclosed
EP-3494122-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE Ustav Organicke Chemie a Biochemie AV CR, v.v.i. (CZ) 2019-06-12 — — EP disclosed
US-20190144486-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-05-16 — — US disclosed
US-20190144486-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2019-05-16 — — US disclosed
WO-2018024265-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE USTAV ORGANICKE CHEMIE A BIOCHEMIE AV CR, V.V.I. (CZ) 2018-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10730905-B2 Substituted heteropentadieno-pyrrolopyrimidine ribonucleosides for therapeutic use DPYD, MTAP, TYMP ADK 664/4885CDK5 2752/4885CDK5R1 2998/4885
US-20190144486-A1 SUBSTITUTED HETEROPENTADIENO-PYRROLOPYRIMIDINE RIBONUCLEOSIDES FOR THERAPEUTIC USE DPYD, MTAP, TYMP ADK 664/4885CDK5 2752/4885CDK5R1 2998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback